The role and mechanism of necrosis in glioblastoma

Active Grant Awarded

Award ID
RF1NS119547
Recipient
Awarding agency
Obligated
$1,538,967

Award facts

Completion date 6% complete
Place of performance
Hershey, PA 17033, USA

Award details come from USAspending.gov.

About this award

The National Institute of Neurological Disorders and Stroke, within the National Institutes of Health and Department of Health and Human Services, awarded Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center, $1.538967 million on September 17, 2026, under Assistance Listing 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders. The assistance type is a grant (Grant RF1NS119547).

The funded work studies the mechanisms of necrosis in glioblastoma, the most common aggressive primary adult brain tumor, and seeks therapeutic vulnerabilities in mesenchymal progression. The approach combines spatially defined gene expression profiling, histological analysis of patient glioblastoma samples, and multiple glioblastoma mouse models. The second-term objective investigates the role of tumor-associated neutrophils in glioblastoma necrosis and the effect of tumor necrosis on anti-tumor immunity, building on prior findings that ferroptosis drives necrotic tumor cell death.

The period of performance runs from September 17, 2026, through ultimate completion on August 31, 2029. Work is performed in Hershey, Pennsylvania (17033). The parent program supports NINDS extramural research, including basic research into the structure and function of the brain and nervous system.

Description

Abstract
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. The poor outcomes from traditional treatments and immunotherapy demand a deeper understanding of the mechanisms underlying the cancer's aggressiveness. Among GBM subtypes, the mesenchymal (MES) group has the worst prognosis. However, IT remains unclear how GBM mesodermal differentiation is achieved. Studies found that tumor cells associated with the necrotic region exhibit higher expression of the MES signature genes, suggesting that the necrotic tumor microenvironment may contribute to MES differentiation and could be exploited as a therapeutic target. The goal of this project is to mechanistically and functionally study GBM necrosis, and identify vulnerabilities of GBM MES progression for therapeutics. By analyzing spatially defined gene expression profiles, examining histological features of patient GBM samples, and utilizing multiple unique GBM mouse models, our previous studies uncovered ferroptosis as a cell death mechanism for GBM necrosis. Blocking ferroptosis can reduce tumor necrosis and inhibit GBM progression. We found that tumor-associated neutrophils (TANS) are responsible for inducing tumor cell ferroptosis. This process relies on the transfer of neutrophil myeloperoxidase to tumor cells via LC3-associated phagocytosis (LAP). In the second term of this project, our specific objective is to further investigate the role of TANS in GBM necrosis and understand the impact of tumor necrosis on anti- tumor immunity. We have established the following premises for the proposed studies. First, we found unexpected expression of intercellular adhesion molecule 1(ICAM1) in tumor cells at the peri-necrotic zone. On the tumor cell membrane, ICAM1 is enriched at the neutrophil-tumor cell interface. ICAM1-decorated tumor cell membrane wraps around neutrophils. Second, we found that tumor cell-killing capable neutrophils possess increased levels of lipid ROS, suggesting that ferroptosis initiated in neutrophils can transfer to tumor cells. Third, we found that neutrophil extracellular traps (NETS) are associated with tumor necrosis. Depletion of peptidyl arginine deiminase 4, an essential gene for NETS, can inhibit GBM progression and necrosis. Furthermore, we found that ferroptotic tumor cells can release both immunostimulatory and immunosuppressive signals. However, under hypoxic conditions, these tumor cells reduce the release of immunostimulatory content. Based on these findings, we propose two specific aims: 1) to determine the essential factors responsible for neutrophils to promote GBM necrosis, and 2) to determine the mechanism by which necrotic tumor cells sequester immune cells and the impact of ferroptosis on anti-tumor immunity in GBM. By dissecting the mechanisms underlying tumor-immune cell interactions in the necrotic tumor area and demonstrating their impact on anti-tumor immunity, this proposal will reveal GBM vulnerabilities and provide novel avenues for GBM therapeutics.

Quick answers

Who received award RF1NS119547?

RF1NS119547 was awarded to Pennsylvania State University by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 17, 2026.

How much is award RF1NS119547 worth?

$1,538,967 has been obligated on RF1NS119547.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award